CamDiab
CamDiab develops CamAPS FX, an adaptive hybrid closed-loop mobile app that automates insulin delivery for people with type 1 diabetes by linking continuous glucose monitors and insulin pumps to its proprietary Cambridge algorithm, with EU MDR-approved CamAPS Liberty extending it to fully closed-loop operation.
- Company typePrivate
- Founded2019
- HeadquartersCambridge, United Kingdom
- Headcount1–10
- GTM typeB2C
- OfferingSoftware
What CamDiab does
CamDiab Ltd is a Cambridge- and London-based private digital health company that develops and commercialises the CamAPS FX mobile application, an adaptive hybrid closed-loop insulin delivery system for people aged one year and older with type 1 diabetes. The app connects to compatible continuous glucose monitors (Dexcom G6/G7, Abbott FreeStyle Libre 3/3 Plus) and insulin pumps (YpsoPump, DANA Diabecare RS, DANA-i), running the proprietary Cambridge self-learning algorithm — refined over 15+ years of research at the University of Cambridge and validated in randomised trials published in The Lancet, NEJM, and Diabetes Care — to compute and direct insulin doses every 8 to 12 minutes. In January 2026 the company received EU MDR notified body approval for CamAPS Liberty, the world's first commercially available fully closed-loop feature, which removes the need for carbohydrate counting and pre-meal bolusing.
CamDiab generates revenue through two complementary streams: direct app subscriptions sold via its website and the Google Play/Apple App Store (£80 per month, £450 per six months, or £840 per year, with a 30-day free trial), and B2B algorithm licensing and OEM integration with device partners — most prominently Ypsomed's mylife Diabetes Care, where CamAPS FX is embedded as the algorithm engine inside the myLoop AID system. Abbott and Dexcom partnerships extend CGM compatibility, while Cambridge Diabetes Education Programme (CDEP) certification provides free healthcare professional training as an indirect adoption driver. The company holds regulatory approvals across six major markets (UK, EU, USA, Canada, Australia, New Zealand), operates with 1-10 employees in a founder-led structure under Professor Roman Hovorka, and pursues growth through market-by-market geographic expansion, additional device integrations, and the staged rollout of its fully closed-loop CamAPS Liberty feature.
CamDiab firmographics
Firmographics- Name
- CamDiab
- Legal name
- CamDiab Ltd
- Website
- https://camdiab.com
- Company type
- Private
- Founded year
- 2019
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- CamDiab develops CamAPS FX, an adaptive hybrid closed-loop mobile app that automates insulin delivery for people with type 1 diabetes by linking continuous glucose monitors and insulin pumps to its proprietary Cambridge algorithm, with EU MDR-approved CamAPS Liberty extending it to fully closed-loop operation.
- Ownership category
- akta.pro rank
CamDiab industry classification
Industry- Product category
- Automated Insulin Delivery Software (Diabetes Management)
- NAICS
- Electromedical and Electrotherapeutic Apparatus Manufacturing (334510), Software Publishers (513210)
- SIC
- Electromedical & Electrotherapeutic Apparatus (3845)
- akta.pro primary industry
- Automated Insulin Delivery (AID) / Closed-Loop Systems (HLAHAHAF)
- akta.pro secondary industry
- Diabetes Digital Therapeutics & Dose Decision Support (Bolus Calculators) (HLAHAHAJ)
Keywords
Where CamDiab is headquartered
LocationHeadquarters
- HQ city
- Cambridge
- HQ country
- United Kingdom
- HQ region
- Europe
Offices2 records
Markets served
CamDiab business model
Business model- GTM type
- B2C
- Offering type
- Software
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure
Revenue model
- CamAPS FX App Subscription: CamAPS FX is sold as a downloadable mobile app with monthly, 6-monthly, and annual subscription options. Subscriptions are purchased through the company website, Google Play, and Apple App Store, or via voucher codes. The app requires users to complete certified online training before activation. Pricing is publicly listed at £80/month, £450 for 6 months, or £840/year (plus VAT unless exempt). A 30-day free trial is available using discount code CamAPS30. Usage fees are payable in advance and non-refundable except in specific circumstances outlined in the T&Cs.
- Healthcare Professional Training Services: CamDiab provides FREE certified online HCP training via the Cambridge Diabetes Education Programme (CDEP). While the training itself is free, it serves as a gatekeeper and adoption driver for clinical prescription and recommendation of CamAPS FX, indirectly driving subscription revenue.
- Algorithm Licensing / OEM Integration: CamDiab's CamAPS algorithm is embedded within Ypsomed's mylife Loop/AID ecosystem and integrated with Abbott's FreeStyle Libre 3 and Dexcom G7. These partnerships suggest a licensing or OEM arrangement where CamDiab's technology is incorporated into partners' AID systems, generating revenue from technology integration fees or per-unit royalties.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Subscription | Monthly | Monthly subscription — £80 per month |
| Subscription | Multi-year contract | 6-month subscription — £450 (£30 saving) |
| Subscription | Annual | Annual subscription — £840 (£120 saving) |
Go-to-market motion3 records
Distribution channels6 records
Marketing channels9 records
CamDiab product offering
Product offeringCore offering
CamDiab develops and commercialises the CamAPS FX mobile application, an adaptive hybrid closed-loop system that automatically adjusts insulin delivery from a compatible insulin pump based on continuous glucose monitor (CGM) readings every 8–12 minutes for people with type 1 diabetes aged one year and over. The app is sold on a subscription basis directly to consumers via app stores and the company website, and is also licensed as the algorithm engine within partner AID ecosystems such as Ypsomed's myLoop system, with Abbott FreeStyle Libre 3 and Dexcom G7 sensor integrations.
Product overview
CamDiab offers a mobile health platform centered on its CamAPS FX app, an advanced adaptive hybrid closed-loop system for automated insulin delivery in type 1 diabetes. The core CamAPS FX app connects to compatible continuous glucose monitors (Dexcom G6/G7, FreeStyle Libre 3/3 Plus) and insulin pumps (YpsoPump, DANA Diabecare RS, DANA-i) to autonomously compute and direct insulin delivery. The company has expanded its portfolio with CamAPS Liberty, the world's first commercially available fully closed-loop feature, which removes the need for carb counting and meal bolusing. CamAPS HX represents an extension for non-type 1 diabetes populations. The platform is complemented by data sharing integrations with mylife Cloud and Glooko, and the Companion feature enabling remote caregiver monitoring.
Differentiator
Problem solved
Functional benefit
Brands
- CamAPS FX: Advanced adaptive hybrid closed-loop mobile app for people with type 1 diabetes that automatically adjusts insulin delivery based on sensor glucose readings.
- CamAPS Liberty
- mylife CamAPS FX
Products and services
- CamAPS FX Advanced adaptive hybrid closed-loop mobile application that automatically adjusts insulin delivery on a compatible insulin pump based on continuous glucose monitor (CGM) sensor readings every 8–12 minutes. Designed for people with type 1 diabetes aged one year and older who use a compatible CGM and insulin pump. Sold via subscription through app stores and the CamDiab website, and licensed into partner AID systems.
- CamAPS Liberty Fully closed-loop feature within the CamAPS FX app that, when activated, removes the need for users to count carbohydrates or deliver pre-meal insulin boluses. The algorithm autonomously handles meal-related insulin dosing while maintaining established safety boundaries, targeting people with type 1 diabetes aged 13 and over.
- CamAPS HX App offering fully closed-loop insulin delivery for non-type 1 diabetes populations, extending the CamAPS algorithm beyond its type 1 diabetes indication.
Quantifiable outcome
- Significant increase in time in range, reduction in HbA1c, reduction in time spent in hypoglycaemia and hyperglycaemia, and improved well-being (randomised clinical trials)
- +4 more outcomes
Companies that use CamDiab
Customer profileNamed customers4 records
Segments3 records
Ideal customer profiles3 records
CamDiab technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Integration9 records
AI capability3 records
Feature6 records
CamDiab partnerships and signals
Strategic signalPartnerships
Five partnerships are on record, tiered core.
- Ypsomed / mylife Diabetes CarecoreCamAPS FX is embedded as the algorithm engine within Ypsomed's mylife Loop/AID ecosystem, integrating the YpsoPump insulin pump with CamAPS FX and compatible sensors. Ypsomed distributes the combined system globally, with the Dexcom G7 integration (June 2026) jointly announced by all three companies. This is CamDiab's primary channel partnership and the largest distribution vehicle for its technology. The partnership enables Ypsomed's customer base to access CamAPS FX's adaptive closed-loop algorithm.
- DexcomcoreDexcom G7 CGM system integration with myLoop/CamAPS FX launched in Switzerland in June 2026, with rollout to 17 additional countries (Australia, Austria, Belgium, Czech Republic, Denmark, Finland, France, Germany, Ireland, Italy, Netherlands, New Zealand, Norway, Poland, Spain, Sweden, United Kingdom) planned by end of June 2026. The integration brings Dexcom G7's fast warm-up time and accuracy to the CamAPS FX ecosystem, expanding sensor choice for users.
- Abbott (FreeStyle Libre)coreAbbott's FreeStyle Libre 2 and FreeStyle Libre 3 integrated CGM systems received FDA clearance for integration into AID systems in the US, enabling connection with CamAPS FX. Abbott also partnered with Ypsomed and CamDiab to integrate FreeStyle Libre 3 with their systems in Germany, with additional European countries to follow. Abbott acquired Bigfoot Biomedical in 2023 and integrated its connected insulin pen caps into the FreeStyle Libre ecosystem, expanding its diabetes management partnerships.
- Cambridge Diabetes Education Programme (CDEP)coreCamDiab provides free certified online training for healthcare professionals through CDEP, the Cambridge Diabetes Education Programme. This training programme is the primary mechanism for driving clinical adoption and prescriber education for CamAPS FX.
- University of CambridgecoreThe CamAPS algorithm was developed at the University of Cambridge over more than 15 years of research (2006–present). The company was spun out from Cambridge University, and founder Professor Roman Hovorka remains affiliated with the university. The Cambridge research programme includes trials in children, adolescents, adults, pregnant women, and elderly patients, providing the clinical evidence base for CamAPS FX.
Scale indicators5 records
Recent moves6 records
Expansion highlights6 records
CamDiab competitors and assessment
Company assessmentEmerging players
- Diabeloop: Diabeloop is a European direct competitor developing hybrid closed-loop algorithms (DBLG1, DBLG2) integrated with pumps and CGMs, comparable in approach to CamAPS FX and active in EU markets.
- Beta Bionics (iLet bionic pancreas): Beta Bionics developed the iLet bionic pancreas with an algorithm that, like CamAPS Liberty, eliminates the need for carb counting. Direct competitor in the fully closed-loop / bihormonal AID space.
Direct peers
- Insulet (Omnipod 5): Insulet's Omnipod 5 is a tubeless patch pump with a hybrid closed-loop algorithm (SmartAdjust) directly competing with CamAPS FX-enabled systems. Targeted to similar type 1 diabetes populations with smartphone-app control.
- Tandem Diabetes Care (t:slim X2 / Control-IQ): Tandem's Control-IQ hybrid closed-loop algorithm on the t:slim X2 pump is a direct competitor to CamAPS FX in adaptive AID for type 1 diabetes. Both target smartphone-connected, multi-CGM-compatible closed-loop insulin delivery.
Others
- Dexcom (G7 CGM + algorithms): Dexcom provides CGM sensor integrations with CamAPS FX (partner) but is also building broader AID ecosystem positioning. Closely tied to CamDiab via Dexcom G7 launch in 17 countries.
- Abbott (FreeStyle Libre / AID ecosystem): Abbott's FreeStyle Libre 3/3+ iCGM is a compatible sensor for CamAPS FX; Abbott is an integration partner. Comparable as a diabetes technology ecosystem player pursuing integrated AID via partnerships and Bigfoot Biomedical acquisition.
- Ypsomed (myLoop / mylife Diabetes Care): Ypsomed is CamDiab's primary channel partner, embedding CamAPS FX into its myLoop AID system via the YpsoPump. Not a competitor but a strategic distribution enabler comparable as a diabetes device company.
Broad incumbents
- Medtronic (MiniMed 780G): Medtronic is the incumbent leader in automated insulin delivery via its 780G hybrid closed-loop system bundling pump, CGM, and algorithm. Competes with CamAPS FX in the hybrid/closed-loop AID category for type 1 diabetes.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat6 records
Key risks6 records
Key highlights7 records
Customer concentration
CamDiab social profiles
Digital presenceCamDiab compliance and trust
Trust signalCompliance6 records
CamDiab financial estimates
Financial estimateRevenue estimate
Valuation estimate
CamDiab leadership team
Management profileNumber of profiles
Profiles1 record
CamDiab funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
CamDiab M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about CamDiab
What does CamDiab do?
CamDiab develops and commercialises the CamAPS FX mobile application, an adaptive hybrid closed-loop system that automatically adjusts insulin delivery from a compatible insulin pump based on continuous glucose monitor (CGM) readings every 8–12 minutes for people with type 1 diabetes aged one year and over. The app is sold on a subscription basis directly to consumers via app stores and the company website, and is also licensed as the algorithm engine within partner AID ecosystems such as Ypsomed's myLoop system, with Abbott FreeStyle Libre 3 and Dexcom G7 sensor integrations.
Is CamDiab a public or private company?
CamDiab is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was CamDiab founded?
CamDiab was founded in 2019. It employs 1 to 10 people.
Where is CamDiab based?
CamDiab is headquartered in Cambridge, United Kingdom, in the Europe region.
How does CamDiab make money?
Three revenue lines are on record. CamAPS FX App Subscription is the primary driver. The others are healthcare Professional Training Services and algorithm Licensing / OEM Integration.
Who are CamDiab's main competitors?
Emerging players on record are Diabeloop and Beta Bionics (iLet bionic pancreas). Direct peers are Insulet (Omnipod 5) and Tandem Diabetes Care (t:slim X2 / Control-IQ). Others are Dexcom (G7 CGM + algorithms), Abbott (FreeStyle Libre / AID ecosystem) and Ypsomed (myLoop / mylife Diabetes Care). Medtronic (MiniMed 780G) is listed as a broad incumbent.
Does CamDiab have an API?
No public API is recorded for CamDiab.
What industry is CamDiab in?
CamDiab's product category is Automated Insulin Delivery Software (Diabetes Management). Its primary akta.pro industry code is HLAHAHAF, Automated Insulin Delivery (AID) / Closed-Loop Systems, with a secondary code of HLAHAHAJ, Diabetes Digital Therapeutics & Dose Decision Support (Bolus Calculators). Its NAICS code is 334510 and its SIC code is 3845.